1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
AML: KOL Insight - 2017

AML: KOL Insight - 2017

  • February 2017
  • ID: 4833561
  • Format: PDF
  • Firstword Pharma


Table of Contents


Will novel targeted therapies change AML treatment pathways?

For decades, chemotherapies have been at the forefront of AML treatment. How is this all set to change within the next few years? Novartis’ midostaurin and Seattle Genetics vadastuximab talirine form part of a rich pipeline, but which drugs stand out to key opinion leaders (KOLs)? Are these agents effective enough to displace chemotherapies and lead to durable remissions? Most importantly, will they improve survival in patients that need it the most?

Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Acute Myeloid Leukaemia (AML).

Twelve US and European KOLs give their insight on two off-label marketed products and 16 pipeline programmes. KOLs also provide their candid views on the potential for novel chemotherapies and early-stage pipeline programmes.

Top Takeaways
- With an urgent need for effective treatment options in AML, what are key players doing to tackle the deadly disease? How can the unmet needs be addressed with novel pipeline therapies?
- Chemotherapies have dominated the treatment algorithm for 40 years, but how is that all set to change within the next 2-3 years? Find out if KOLs believe chemotherapies will continue to play a key part in AML treatment, and how the landscape could evolve.
- Four FLT3 inhibitors are in the pipeline; what impact are they likely to have and how can they successfully differentiate themselves? Novartis’ midostaurin is leading the race with next generation FLT3 inhibitors hot on its heels. Find out how KOLs will weigh up these new drug options.
- How do KOLs feel about other personalised approaches and will they shape treatment? Celgene/Agios’ IDH2 inhibitor enasidenib and Roche’s idasanutlin are targeting specific pathways in AML, where do KOLs see these niche agents fitting in?
- Durable responses are a must, so how does this factor into KOL opinions about novel drugs? Maintaining durable remissions is crucial in AML. Find out which drugs KOLs think will be best suited to maintain patients in remission and prevent relapses.
- Is Seattle Genetics’s anti-CD33 agent, vadastuximab talirine, poised for success or will it face similar hurdles as Pfizer’s Mylotarg? Mylotarg had safety issues but how do KOLs view vadastuximab’s potential?
- Will novel chemotherapies have a chance to improve upon older agents and if so, what challenges do they face? Novel chemotherapies such as Jazz Pharmaceuticals’ Vyxeos and Astex’ guadecitabine are hoping to compete with conventional standard-of-care regimens. Find out what KOLs think about this.
- What other early-stage pipeline programmes are KOLS particularly excited about? The early-stage pipeline for AML has diverse mechanisms in Phase II development. AbbVie/Roche’s venetoclax has been a game-changer in CLL but does the same hold true for AML?
- Combination approaches versus monotherapies; what will succeed in AML? Efficacy, safety and convenience of administration will all play an important role in determining preferred treatments but why are some approaches favoured over others?

“Hopefully, over the next five years, we will first of all see an emergence of widespread availability of these targeted small molecule agents; specifically the FLT3 inhibitors and the IDH1/2 inhibitors, I think they are the most promising compounds.” EU Key Opinion Leader

“FLT3 inhibitors, IDH inhibitors, venetoclax; those are very real and I think those will come to the market very quickly. The others are perhaps the monoclonal antibodies, I expect those to make it. I think those are more realistic and the other [drugs] are possibilities but a little further behind.” US Key Opinion Leader

Marketed Therapies (off-label)
- Nexavar (sorafenib; Bayer/Onyx Pharma)
- Mylotarg (Pfizer)

Pipeline Therapies
- midostaurin (Novartis)
- quizartinib (Daiichi Sankyo)
- gilteritinib (Astellas Pharma)
- enasidenib (Celgene/Agios Pharma)
- vadastuximab talirine (Seattle Genetics)
- Vyxeos (CPX-351; Jazz Pharmaceuticals)
- Venclexta/Venclyxta (venetoclax; AbbVie/Roche)

KOLs from North America
- Dr Farhad Ravandi, MD, Professor and Chief in the Department of Leukaemia at MD Anderson, Houston, Texas.
- Dr Elihu Estey, MD, Professor of Medicine, Division of Hematology, University of Washington School of Medicine, Seattle.
- Dr Jorge Cortes, MD, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

KOLs from Europe
- Professor Alan Burnett, MD, PhD, Professor and Head of the Department of Haematology at the University of Wales College of Medicine, Cardiff, UK.
- Professor Francesco Lo-Coco, MD, PhD, Full Professor of Haematology and Head of the Laboratory of Integrated Diagnosis of Oncohaematologic Diseases at the Department of Biopathology of the University Tor Vergata of Roma, Italy.
- Professor Xavier Thomas, MD, Department of Haematology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on